Abstract 125P
Background
The Network meta-analysis (NMA) of survival data is often based on the reported hazard ratios and relies on the proportional hazard (PH) assumption. To address the violation of the PH assumption, a non-proportional hazard (NPH) NMA was conducted using pseudo-patient-level data to assess the comparative efficacy of PD-1 inhibitors and chemotherapy in second-line treatment for advanced esophageal squamous cell carcinoma.
Methods
Embase and MEDLINE databases were searched for randomized controlled trials (RCTs) assessing PD-1 inhibitors for the treatment of ESCC. The Kaplan-Meier curves of overall survival (OS) from selected studies were digitized to generate pseudo-patient-level data using the Guyot algorithm. PH assumption testing was performed for all included studies and was found to be violated in multiple studies. A series of parametric models were fitted to the pseudo-patient-level data generated from the available KM curves using the method suggested by Ouwens et. al. The parametric NMA was performed using the “survivalnma” package in R. The Gelman-Rubin diagnostic, a measure of convergence for a list of Markov chain Monte Carlo (MCMC) sequences, was used to evaluate the convergence of the model.
Results
Five parametric distribution-based models (Exponential, Weibull, Gompertz, Log-normal, and Log-logistic) were considered for the NPH NMA. Based on the goodness of fit statistic, the best-fitted model was log-normal having a deviance information criterion (DIC) is 1445.7. The 3-year predicted survival of camrelizumab, nivolumab, sintilimab, pembrolizumab, tislelizumab and chemotherapy was 12%, 12%, 16%, 11%, 16% and 4%, respectively. The results should be interpreted with caution as the included trials were heterogeneous in terms of sample size, trial setting, and geography.
Conclusions
Parametric NMA is suitable for analyzing the comparative efficacy of multiple treatments in the presence of NPH as these methods leverage the use of distributional estimates (shape and scale) to conventional parametric survival models, fitted to patient-level data from the studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Heorlytics PVT. Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02
119P - Clinicopathological features and roles of lymph node metastases in gastric cancer: A single-center retrospective study in China
Presenter: yuming zhang
Session: Poster viewing 02
120P - Clinical implication of DNA damage response gene in advanced gastric cancer stage IV and recurrent gastric cancer patients after gastrectomy treated palliative chemotherapy
Presenter: In Gyu Hwang
Session: Poster viewing 02
121P - Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
Presenter: Amrith B P
Session: Poster viewing 02
122P - Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
Presenter: Amrith B P
Session: Poster viewing 02
123P - Sarcomatoid carcinoma of gall bladder: A series of 14 cases from a single tertiary-care oncology centre
Presenter: Subhash Yadav
Session: Poster viewing 02
124P - Clinical profile and treatment outcomes of hepatocellular carcinoma from a tertiary care hospital in South India: A retrospective study
Presenter: Gayathri Nair
Session: Poster viewing 02
126P - Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Presenter: Keitaro Shimozaki
Session: Poster viewing 02
127P - LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Presenter: Jirapat Wonglhow
Session: Poster viewing 02
128P - Survival outcome of gastric cancer patients in a tertiary care center: A 10-year single center retrospective study
Presenter: Dawn Lynn Guardiario
Session: Poster viewing 02